Drug Profile


Alternative Names: EMD 675992; GRC 8200

Latest Information Update: 15 Sep 2015

Price : $50

At a glance

  • Originator Glenmark Pharmaceuticals Ltd
  • Class Antihyperglycaemics; Nitriles; Pyrrolidines; Small molecules; Triazoles
  • Mechanism of Action CD26 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Type 2 diabetes mellitus

Most Recent Events

  • 15 Sep 2015 No recent reports on development identified - Phase-II for Type-2 diabetes mellitus in India and South Africa (PO)
  • 01 Jul 2009 Melogliptin is available for licensing (
  • 24 Jun 2009 Final efficacy and adverse events data from a phase IIb trial in type 2 diabetes released by Glenmark Pharmaceuticals Ltd
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top